Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-34

So, back to the 4c

As Eddie has pointed out, these revenue numbers are indeed impressive. I have mentioned the growth & trajectory of Creso many times on here over the last couple of years, and the trend continues - rapid and constant.

I called revenue at $A7-8 million for this FY. I'll call it - right here, right now - at $A13-15 mil for CY 2022. And into the 20's for 2023 ......... then there's your 40c share price.

Mernova can EASILY take $A4 mil per quarter in the near term. Their THC brands are definitely gaining traction - with the US still on the horizon. Well done Jack Wu.

CBD/pet products can triple to $A3 mil without much extra input or associated costs - the setups have already been established.

ImpActive is an interesting one. It's the Trojan Horse taking our CBD into the US. Ice Hockey players are big celebrities over there (and they take a beating !) and their endorsement gives Creso's products a significant point of difference. Watch this one grow fast.

This Quarterly represents a cultural change in the attitude of management - it's glaringly obvious. The American's fingerprints are all over this report.

OK bashers - go back to talking about CPH from 2/3 years ago.